Frankfurt
03.04.25
08:11 Uhr
1,316 Euro
+0,028
+2,17 %
+2,17 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.02. | Orexo AB: Orexo Interim Report Q4 2024, incl. Full Year Report | 46 | GlobeNewswire (Europe) | Q4 2024 highlights› Total net revenues of SEK 160.3 m (166.0)› EBITDA of SEK 28.9 m (12.4)› Impairment of intangible assets Deprexis® of SEK 71.1 m (0) and Vorvida® of SEK 28.1 m (0)› Net earnings of... ► Artikel lesen | |
| 10.01. | Orexo Announces Positive Data From Clinical Study Of OX640 Evaluating Allergic Reactions | 1 | RTTNews | ||
| 10.01. | Orexo announces positive topline data from clinical study of OX640 in subjects with and without allergic rhinitis | 361 | PR Newswire | OX640 is a nasal rescue medication with powder-based epinephrine for the treatment of allergic reactions (incl. anaphylaxis) and is based on the proprietary AmorphOX® technology.The clinical... ► Artikel lesen | |
| 18.12.24 | Abera and Orexo partner for vaccine powder formulations | 2 | Pharmaceutical Technology | ||
| 17.12.24 | Orexo, Abera to develop nasal powder vaccines based on AmorphOX technology | 2 | Seeking Alpha | ||
| 17.12.24 | Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology | 435 | PR Newswire | The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®.Abera is a developer of mucosal vaccines and has several preclinical... ► Artikel lesen | |
| 02.12.24 | Orexo exits depression DTx alliance with GAIA | 1 | pharmaphorum | ||
| 02.12.24 | Orexo AB: Orexo and GAIA agree to terminate the partnership for Deprexis | 240 | GlobeNewswire (Europe) | Uppsala, Sweden - December 2, 2024 - Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), today announces that Orexo AB and GAIA AG have decided to terminate the partnership agreement, covering the rights for... ► Artikel lesen | |
| OREXO Aktie jetzt für 0€ handeln | |||||
| 25.10.24 | Orexo initiates new study of OX640 in participants with allergic rhinitis | 288 | PR Newswire | OX640 is an intranasal rescue medication for the treatment of severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine.OX640 is based on Orexo's proprietary drug delivery... ► Artikel lesen | |
| 24.10.24 | Orexo AB reports Q3 results | 1 | Seeking Alpha | ||
| 24.10.24 | Orexo Interim Report Q3 2024 | 434 | PR Newswire | UPPSALA, Sweden, Oct. 24, 2024 /PRNewswire/ --
Q3 2024 highlights
› Total net revenues of SEK 136.5 m (156.1)
› EBITDA of SEK -0.7 m (-9.5)
› Net earnings of SEK -41.9... ► Artikel lesen | |
| 04.10.24 | Orexo's Nomination Committee for the Annual General Meeting 2025 | 301 | PR Newswire | UPPSALA, Sweden, Oct. 4, 2024 /PRNewswire/ -- The members of the Nomination Committee for the Annual General Meeting (AGM), that takes place on May 8, 2025, have been appointed and comprises... ► Artikel lesen | |
| 03.09.24 | Orexo to participate in Pareto Securities' 15th Annual Healthcare Conference 2024 | 301 | PR Newswire | UPPSALA, Sweden, Sept. 3, 2024 /PRNewswire/ -- Orexo AB (Publ.), (STO: ORX) (OTCQX: ORXOY), today announces the company will participate in Pareto Securities' 15th Annual Healthcare Conference... ► Artikel lesen | |
| 17.07.24 | Orexo Q2 2024 Interim Report | 395 | PR Newswire | UPPSALA, Sweden, July 17, 2024 /PRNewswire/ --
Making progress, while the OX124 review time extended
Q2 2024 highlights
Total net revenues of SEK 154.0 m (157.7)EBITDA of SEK... ► Artikel lesen | |
| 16.07.24 | Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose | 390 | PR Newswire | UPPSALA, Sweden, July 16, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food... ► Artikel lesen | |
| 10.07.24 | Orexo AB's sustainability work ranked among top 5% by EcoVadis | 443 | PR Newswire | UPPSALA, Sweden, July 10, 2024 /PRNewswire/ -- Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world's most trusted... ► Artikel lesen | |
| 08.07.24 | Orexo: invitation to presentation of the Q2 2024 Interim Report | 399 | PR Newswire | UPPSALA, Sweden, July 8, 2024 /PRNewswire/ -- As previously communicated Orexo will announce the Interim Report for the second quarter of 2024 on July 17 at 8 am CET. The same day at 2 pm... ► Artikel lesen | |
| 10.05.24 | Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm | 914 | PR Newswire | UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating... ► Artikel lesen | |
| 08.05.24 | Orexo Q1 2024 Interim Report | 438 | PR Newswire | UPPSALA, Sweden, May 8, 2024 /PRNewswire/ --
Starting 2024 with a positive EBITDA
Q1 2024 highlights
Total net revenues of SEK 139.3 m (158.8)EBITDA of SEK 15.9 m (-41.1)Net... ► Artikel lesen | |
| 26.04.24 | Report from Orexo AB's annual general meeting, 26 April 2024 | 337 | PR Newswire | UPPSALA, Sweden, April 26, 2024 /PRNewswire/ --
Election of the board of directors and auditor
The annual general meeting in Orexo AB (publ) on 26 April 2024 resolved, in accordance... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AURORA CANNABIS | 3,888 | -5,31 % | Stocks in Play: Aurora Cannabis Inc. | ||
| ABBVIE | 184,20 | -2,56 % | AbbVie-Aktie mit Kursgewinnen (193,3778 €) | An der US-amerikanischen Börse liegt die AbbVie-Aktie gegenwärtig im Plus. Das Wertpapier notiert zur Stunde bei 209,14 US-Dollar. Im US-amerikanischen Wertpapierhandel hat sich heute die AbbVie-Aktie... ► Artikel lesen | |
| TILRAY BRANDS | 0,556 | -7,55 % | Tilray Brands Inc: Tilray moves Good Supply Jean Guy cultivation to Quebec | ||
| BRISTOL-MYERS SQUIBB | 53,55 | -2,49 % | Halozyme: Bristol Myers Squibb Secures CHMP's Positive Opinion For New Cancer Drug Delivery Method | NEW YORK CITY (dpa-AFX) - Halozyme Therapeutics, Inc. (HALO), Monday announced that Bristol Myers Squibb (BMY) received a positive opinion from the Committee for Medicinal Products for Human... ► Artikel lesen | |
| TEVA | 13,550 | -3,90 % | Medincell's Partner Teva Presented Phase 3 Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with Olanzapine LAI | Regulatory News:
Medincell (Paris:MEDCL):
More than 92% of schizophrenia patients taking Olanzapine LAI in the Phase 3 SOLARIS survey were satisfied or very satisfied with the initiation regimen... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 442,90 | -0,59 % | Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $420.00 | ||
| EYEPOINT PHARMACEUTICALS | 4,250 | -14,05 % | What is Chardan Capital's Forecast for EYPT FY2026 Earnings? | ||
| BAUSCH HEALTH | 5,944 | +5,45 % | Bausch Health Companies Inc.: Patient Voices Highlight the Realities of Living with Irritable Bowel Syndrome During IBS Awareness Month | Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed... ► Artikel lesen | |
| EDWARDS LIFESCIENCES | 66,40 | 0,00 % | Edwards Lifesciences Aktie: Wendepunkt, oder nicht? | Das Medizintechnikunternehmen verzeichnet Umsatzwachstum trotz Kursrückgang, wobei innovative Katheter-Therapien die Geschäftsentwicklung maßgeblich vorantreiben. Edwards Lifesciences verzeichnete im... ► Artikel lesen | |
| BIONANO GENOMICS | 3,340 | -11,41 % | Bionano Genomics: Bionano Reports Fourth Quarter and Full-Year 2024 Results and Provides Revenue Outlook for 2025 | SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,560 | -10,59 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| AMARIN | 0,380 | -5,00 % | AMARIN CORP PLC - 8-K, Current Report | ||
| OPKO HEALTH | 1,465 | -3,96 % | Hedge Fund and Insider Trading News: Ray Dalio, Michael Platt, Paul Marshall, Bill Ackman, Brevan Howard, OPKO Health Inc (OPK), Carvana Co (CVNA), and More | ||
| JAGUAR HEALTH | 4,500 | -0,22 % | Jaguar Health, Inc.: Jaguar Health Announces Closing of Bridge Financing Priced At-The-Market Under Nasdaq Rules | SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement.Jaguar's... ► Artikel lesen | |
| ENDO | - | - | Endo, Inc.: Endo Presents Dupuytren Contracture Data at the IFSSH and IFSHT Triennial Congress | MALVERN, Pa., March 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that data related to the use of XIAFLEX® (collagenase clostridium histolyticum, or CCH) for the treatment... ► Artikel lesen |
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OREXO AB finden Sie auf Wallstreet Online.
